Meridian Bioscience Inc. (NASDAQ:VIVO) declared a quarterly dividend on Thursday, July 27th, Fidelity reports. Stockholders of record on Monday, August 7th will be paid a dividend of 0.125 per share on Thursday, August 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, August 3rd.

Shares of Meridian Bioscience (NASDAQ VIVO) traded down 2.39% during trading on Friday, hitting $14.30. The stock had a trading volume of 51,275 shares. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $19.86. The company has a market cap of $603.49 million, a PE ratio of 20.17 and a beta of 0.91. The firm’s 50 day moving average is $15.31 and its 200 day moving average is $14.23.

Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. Meridian Bioscience had a net margin of 15.02% and a return on equity of 18.02%. The business had revenue of $50.14 million during the quarter, compared to analyst estimates of $49.13 million. During the same period in the prior year, the business posted $0.21 earnings per share. The company’s revenue was down 1.0% on a year-over-year basis. Equities research analysts anticipate that Meridian Bioscience will post $0.68 EPS for the current fiscal year.

Several research firms have issued reports on VIVO. Zacks Investment Research lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. BidaskClub lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, Canaccord Genuity upped their price target on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.75.

COPYRIGHT VIOLATION NOTICE: “Meridian Bioscience Inc. Plans Quarterly Dividend of $0.13 (NASDAQ:VIVO)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/28/meridian-bioscience-inc-plans-quarterly-dividend-of-0-13-nasdaqvivo.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Dividend History for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.